Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
Reads0
Chats0
TLDR
Lenalidomide is a lead therapeutic in multiple myeloma and deletion 5q myelodysplastic syndromes and shows promising activities in other hematologic malignancies and its pharmacokinetics are consistent across patient populations, regardless of the type of hematological malignancy.Abstract:
Lenalidomide is a lead therapeutic in multiple myeloma and deletion 5q myelodysplastic syndromes and shows promising activities in other hematologic malignancies. This article presents a comprehensive review of the clinical pharmacokinetics and pharmacodynamics of lenalidomide. Oral lenalidomide is rapidly and highly absorbed (>90 % of dose) under fasting conditions. Food affects oral absorption, reducing area under the concentration–time curve (AUC) by 20 % and maximum concentration (C
max) by 50 %. The increase in AUC and C
max is dose proportional, and interindividual variability in plasma exposure is low to moderate. Lenalidomide distributes into semen but is undetectable 3 days after stopping treatment. Biotransformation of lenalidomide in humans includes chiral inversion, trivial hydroxylation, and slow non-enzymatic hydrolysis. Approximately 82 % of an oral dose is excreted as lenalidomide in urine within 24 h. Lenalidomide has a short half-life (3–4 h) and does not accumulate in plasma upon repeated dosing. Its pharmacokinetics are consistent across patient populations, regardless of the type of hematologic malignancy. Renal function is the only important factor affecting lenalidomide plasma exposure. Lenalidomide has no QT prolongation risk at approved doses, and higher plasma exposure to lenalidomide is associated with increased risk of neutropenia and thrombocytopenia. Despite being a weak substrate of P-glycoprotein (P-gp) in vitro, lenalidomide does not have clinically significant pharmacokinetic interactions with P-gp substrates/inhibitors in controlled studies. The AUC-matched dose adjustment is recommended for patients with renal impairment at the start of therapy. No dose adjustment for lenalidomide is needed on the basis of age, ethnicity, mild hepatic impairment, or drug–drug interactions.read more
Citations
More filters
Summary of product characteristics
Helen Andrew,Gemma Gossedge,Julie Croft,Neil Corrigan,Julia Brown,Nicholas West,Philip Quirke,Damian Tolan,Ronan A. Cahill,David Jayne +9 more
TL;DR: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Journal ArticleDOI
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.
Katherine A. Donovan,Jian An,Radosław P. Nowak,Jingting C. Yuan,Emma C. Fink,Bethany C Berry,Benjamin L. Ebert,Benjamin L. Ebert,Eric S. Fischer +8 more
TL;DR: It is found that thalidomide induces degradation of SALL4 exclusively in humans, primates, and rabbits, but not in rodents or fish, providing a mechanistic link for the species-specific pathogenesis of thalidOMide syndrome.
Journal ArticleDOI
Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics.
TL;DR: The data provided are useful for the therapeutic monitoring of pharmacotherapies, to facilitate the diagnostic assessment and monitoring of acute and chronic intoxications as well as to support forensic and clinical expert opinions.
Journal ArticleDOI
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
James L. Rubenstein,Huimin Geng,Eleanor J. Fraser,Paul Formaker,Lingjing Chen,Jigyasa Sharma,Phoebe Killea,Kaylee Choi,Jenny Ventura,John Kurhanewicz,Clifford A. Lowell,Jimmy Hwang,Patrick A. Treseler,Penny K. Sneed,Jing Li,Xiaomin Wang,Nianhang Chen,Jon A. Gangoiti,Pamela N. Munster,Bertil Damato +19 more
TL;DR: It is concluded that lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas and delays whole brain radiotherapy (WBRT) in patients with inadequate responses to lenalidumide.
Journal ArticleDOI
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan,Max Jan,Irene Scarfò,Rebecca C. Larson,Amanda Walker,Amanda Walker,Amanda Walker,Andrea Schmidts,Andrew A Guirguis,Andrew A Guirguis,Jessica A. Gasser,Jessica A. Gasser,Mikolaj Slabicki,Mikolaj Slabicki,Amanda A. Bouffard,Ana P. Castano,Michael Kann,Maria L. Cabral,Alexander Tepper,Alexander Tepper,Daniel E Grinshpun,Daniel E Grinshpun,Adam S. Sperling,Adam S. Sperling,Taeyoon Kyung,Quinlan L. Sievers,Michael E. Birnbaum,Marcela V. Maus,Marcela V. Maus,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +31 more
TL;DR: In this article, the authors developed ON and OFF switches for CAR T cells using the clinically approved drug lenalidomide, which mediates the proteasomal degradation of several target proteins by inducing interactions between the CRL4CRBN E3 ubiquitin ligase and a C2H2 zinc finger degron motif.
References
More filters
Journal ArticleDOI
Membrane transporters in drug development.
Kathleen M. Giacomini,Shiew-Mei Huang,Donald J. Tweedie,Leslie Z. Benet,Kim L. R. Brouwer,Xiaoyan Chu,Amber Dahlin,Raymond Evers,Volker Fischer,Kathleen M. Hillgren,Keith Hoffmaster,Toshihisa Ishikawa,Dietrich Keppler,Richard B. Kim,Caroline A. Lee,Mikko Niemi,Joseph W. Polli,Yuicchi Sugiyama,Peter W. Swaan,Joseph A. Ware,Stephen H. Wright,Sook Wah Yee,Maciej J. Zamek-Gliszczynski,Lei Zhang +23 more
TL;DR: Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions, as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Summary of product characteristics
Helen Andrew,Gemma Gossedge,Julie Croft,Neil Corrigan,Julia Brown,Nicholas West,Philip Quirke,Damian Tolan,Ronan A. Cahill,David Jayne +9 more
TL;DR: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios A. Dimopoulos,Andrew Spencer,M. Attal,H. Miles Prince,Jean Luc Harousseau,Anna Dmoszynska,Jesús F. San Miguel,Andrzej Hellmann,Thierry Facon,Robin Foà,Alessandro Corso,Zvenyslava Masliak,Marta Olesnyckyj,Zhinuan Yu,John Patin,Jerome B. Zeldis,Robert Knight +16 more
TL;DR: Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Donna M. Weber,Christine Chen,Ruben Niesvizky,Michael Wang,Andrew Belch,Edward A. Stadtmauer,David S. Siegel,Ivan Borrello,S. Vincent Rajkumar,Asher A. Chanan-Khan,Sagar Lonial,Zhinuan Yu,John Patin,Marta Olesnyckyj,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide plus dexamethasone is superior to placebo plus DexamethAsone in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F. List,Gordon W. Dewald,John M. Bennett,A. Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard Stone,Craig B. Reeder,Kenton Wride,John Patin,Michele Schmidt,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.